0001695357 true 0001695357 2022-10-04 2022-10-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K/A

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): October 4, 2022

 

Provention Bio, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38552   81-5245912

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

55 Broad Street, 2nd Floor

Red Bank, NJ

   07701
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (908) 336-0360

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.0001 par value per share   PRVB   The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Explanatory Note

 

Provention Bio, Inc. (the “Company”) is filing this Amendment No. 1 to Current Report on Form 8-K/A (this “Amendment”) to amend the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on October 6, 2022 (the “Original Filing”).

 

As disclosed in the Original Filing, on October 4, 2022, the Company and Genzyme Corporation, a fully-owned subsidiary of Sanofi S.A. (“Sanofi”) entered into a Co-Promotion Agreement (the “Sanofi Co-Promotion Agreement”). Simultaneously with their entry into the Sanofi Co-Promotion Agreement, the Company and Sanofi also entered into a Securities Purchase Agreement (the “Purchase Agreement”).

 

The Company is filing this Amendment solely to file the Sanofi-Co Promotion Agreement and the Purchase Agreement as exhibits. Except as expressly set forth herein, this Amendment does not amend, modify or update the disclosures contained in the Original Filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
     
10.1   Co-Promotion Agreement, dated October 4, 2022, between Provention Bio, Inc. and Genzyme Corporation.
     
10.2   Securities Purchase Agreement, dated October 4, 2022, between Provention Bio, Inc. and Aventis Inc.
     
99.1   Press Release issued by Provention Bio, Inc. on October 6, 2022 (incorporated by reference to the Original Filing).
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Provention Bio, Inc.
     
Dated: March 24, 2023 By: /s/ Thierry Chauche
    Thierry Chauche
    Chief Financial Officer

 

 

 

Provention Bio (NASDAQ:PRVB)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024 Haga Click aquí para más Gráficas Provention Bio.
Provention Bio (NASDAQ:PRVB)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024 Haga Click aquí para más Gráficas Provention Bio.